67962-19-0

Upstream product

• 75-97-8 3,3-dimethyl-butan-2-one 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 1400633-43-3 4-(3-tert-butyl-5-(4-fluorophenyl)-4,5-dihydro-1H-pyrazol-1-yl)benzenesulfonic acid 
• 135426-67-4 C₂₄H₂₇FNO₅P^(2-)*2Na⁽¹⁺⁾ 
• 135426-70-9 Sodium; (S)-4-{[6-tert-butyl-4-(4-fluoro-phenyl)-2-isopropyl-pyridin-3-ylmethoxy]-hydroxy-phosphoryl}-3-hydroxy-butyrate 
• 135426-68-5 (S,E)-4-[[2-[6-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-2-(1-methylethyl)-3-pyridinyl]ethenyl]hydroxyphosphinyl]-3-hydroxybutanoic acid, disodium salt 
• 135426-69-6 (S)-4-[[2-[6-(1,1-Dimethylethyl)-4-(4-fluorophenyl)-2-(1-methylethyl)-3-pyridinyl]ethyl]hydroxyphosphinyl]-3-hydroxybutanoic acid, disodium salt 
• 137586-70-0 (S)-4-({2-[6-tert-Butyl-4-(4-fluoro-phenyl)-2-isopropyl-pyridin-3-yl]-ethyl}-methoxy-phosphinoyl)-3-hydroxy-butyric acid methyl ester 
• 135426-43-6 3-(2,2-Dibromoethenyl)-6-(1,1-dimethylethyl)-4-(4-fluorophenyl)-2-(1-methylethyl)pyridine 
• 122252-63-5 3-(4-Fluorophenyl)-6,6-dimethyl-2-(2-methyl-1-oxopropyl)-5-oxoheptanoic acid, ethyl ester 

Relevant academic research and scientific papers

Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors

Celecoxib, is a selective cyclooxygenase-2 (COX2) inhibitor with a 1,5-diaryl pyrazole scaffold. Celecoxib has a better safety profile compared to other COX2 inhibitors having side effects of systemic hypertension and thromboembolic complications. This may be partly attributed to an off-target activity involving phosphodiesterase 5 (PDE5) inhibition and the potentiation of NO/cGMP signalling allowing coronary vasodilation and aortic relaxation. Inspired by the structure of celecoxib, we synthesized a chemically diverse series of compounds containing a 1,3,5-trisubstituted pyrazoline scaffold to improve PDE5 inhibitory potency, while eliminating COX2 inhibitory activity. SAR studies for PDE5 inhibition revealed an essential role for a carboxylic acid functionality at the 1-phenyl and the importance of the non-planar pyrazoline core over the planar pyrazole with the 5-phenyl moiety tolerating a range of substituents. These modifications led to new PDE5 inhibitors with approximately 20-fold improved potency to inhibit PDE5 and no COX-2 inhibitory activity compared with celecoxib. PDE isozyme profiling of compound 11 revealed a favorable selectivity profile. These results suggest that trisubstituted pyrazolines provide a promising scaffold for further chemical optimization to identify novel PDE5 inhibitors with potential for less side effects compared with available PDE5 inhibitors used for the treatment of penile erectile dysfunction and pulmonary hypertension.

COMPOUNDS AND METHODS FOR TREATING OR PREVENTING HEART FAILURE

The present invention relates to the discovery of novel compounds that can be used to treat and/or prevent heart failure in a subject. In certain embodiments, the compounds of the invention are sulfide: quinone oxidoreductase (SQOR) inhibitors. In other e

Long chain dicationic phase transfer catalysts in the condensation reactions of aromatic aldehydes in water under ultrasonic effect

Long chain dicationic ammonium salts were used successfully as phase transfer catalyst in the condensation reactions of aromatic aldehydes in water under ultrasonic irradiation for the first time. The quaternary salt having longer distance between the cation centers was more effective than the mono- and dicationic ones having short chain.

PYRIDINE ANCHORS FOR HMG-COA REDUCTASE INHIBITORS

Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have a quinoline or a pyridine anchor attached by means of a linker to a binding domain sidechain, which compounds inhibit the e

Phosphorus-Containing Inhibitors of HMG-CoA Reductase. 2. Synthesis and Biological Activites of a Series of Substituted Pyrydynes Containing a Hydroxyphosphinyl Moiety

A series of 2,3,4,(5),6-substituted pyridines containing a hydroxyphosphinyl functionality have been prepared and were evaluated for their ability to inhibit the enzyme HMG-CoA reductase.Systematic substitution of both R1-R4 and X-Y